Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial

Pinyol, Roser; Montal, Robert; Takayama, T.; Chau, Gar‐Yang; Mazzaferro, Vincenzo; Roayaie, Sasan; Lee, H.C.; Poon, Rtp; Kokudo, Norihiro; Zhang, Z.; Bassaganyas, Laia; Torrecilla, Sara; Rodríguez‐Carunchio, Leonardo; Gane, Ed; Verslype, Chris; Croitoru, Adina; Cillo, U.; Mata, Manuel de la; Lupo, L.; Strasser, Simone I.; Park, J.-W.; Camps, Jordi; Solé, María; Thung, S N; Villanueva, A.; Peña, Carol; Meinhart, G.; Bruix, Jordi; Llovet, J.M.

doi:10.1016/s0168-8278(17)30287-8

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the biomarkers tested so far fulfil these criteria in HCC. 278 There is room for further refinement of prognosis evaluation. Liver function has traditionally been assessed through the Child-Pugh classification, which is known to have limited predictive power as temporary events not fully captured (renal failure, spontaneous bacterial peritonitis, hyponatremia, recurrent encephalopathy or malnutrition) may indicate end-stage liver disease, requiring transplant.…”

Section: Staging Systemsmentioning

confidence: 99%

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Galle¹,

Forner²,

Llovet³

et al. 2018

Journal of Hepatology

6,730

4,351

View full text Add to dashboard Cite

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.

show abstract

Section: Staging Systemsmentioning

confidence: 99%

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Galle¹,

Forner²,

Llovet³

et al. 2018

Journal of Hepatology

6,730

4,351

View full text Add to dashboard Cite

show abstract

“…76 In a biomarker study of the STORM trial, gene signatures failed to predict recurrence or prevention of HCC recurrence associated with adjuvant sorafenib use. 77 In HCV-induced HCC, examining tumor tissue identified genetic signatures enriched with immune cells in approximately 24% of cases, which were further subdivided based on the tumor microenviroment. An active immune response within the stroma was an independent predictor of overall survival in patients who underwent resection for HCC.…”

Section: Diagnosis Of Hccmentioning

confidence: 99%

Epidemiology and Management of Hepatocellular Carcinoma

2019

View full text Add to dashboard Cite

The major risk factors for hepatocellular carcinoma (HCC) in a contemporary clinical practice is becoming increasingly related to post sustained virological response hepatitis C, suppressed hepatitis B virus on treatment, alcoholic and non-alcoholic fatty liver disease. We review the emerging data on the risk and determinants of HCC in these conditions, and the implications to HCC surveillance. However, from a public health perspective, active hepatitis C and B continue to drive most of the global burden of HCC. In United States, the age adjusted incidence rates of HCC in Hispanics have surpassed that of Asians. Prognosis in HCC is complex due to the competing risk imposed by underlying cirrhosis and presence of malignancy. In addition to tumor burden, liver function and performance status, additional parameters including tumor biopsy, serum markers and sub classification of current staging systems, taking into account patterns of tumor progression, may improve patient selection for therapy. Advancements in the treatment of HCC has included identification of patients that are most likely to derive a clinically significant benefit from the available therapeutic options. Additionally, the combination strategies of locoregional therapies and/or systemic therapy are being investigated.

show abstract

“…The incidence of HCC will continue to escalate as hepatitis C reaches its maturity and as non-alcoholic steatohepatitis (NASH) and obesity become more prevalent in the United States, and the Centre for Disease Control (CDC) has proposed a series of screening recommendations based on risk exposures [ 3 ]. The development of HCC is complex, involving sustained inflammatory damage leading to hepatocyte necrosis, regeneration, and fibrotic deposition [ 4 ]. This review summarises current knowledge regarding the epidemiology and various risk factors for the development of HCC, with a brief note on various prevention strategies.…”

Section: Introductionmentioning

confidence: 99%

Update in global trends and aetiology of hepatocellular carcinoma

Rawla¹,

Sunkara²,

Muralidharan³

et al. 2018

228

202

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver responsible for an increasing number of cancer-related deaths, especially in developing economies of Asia and Africa. A plethora of risk factors have been described in the literature. Some of the important ones include chronic viral hepatitis, liver cirrhosis, environmental toxins such as aflatoxin, non-alcoholic fatty liver disease, lifestyle factors like alcohol consumption, smoking, and dietary factors, metabolic diseases like diabetes mellitus and obesity, and genetic and hereditary disorders. The development of HCC is complex involving sustained inflammatory damage leading to hepatocyte necrosis, regeneration, and fibrotic deposition. It also poses multiple challenges in diagnosis and treatment despite advances in diagnostic, surgical, and other therapeutic advancements. This is a narrative review of findings of multiple studies that were retrieved from electronic databases like PubMed, MEDLINE, Embase, Google Scholar, Scopus, and Cochrane. We summarise the current knowledge regarding the epidemiology and various risk factors for the development of HCC with a brief note on various prevention strategies.

show abstract

Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial

Cited by 7 publications

References 0 publications

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Epidemiology and Management of Hepatocellular Carcinoma

Update in global trends and aetiology of hepatocellular carcinoma

Contact Info

Product

Resources

About